Polaris AI Pharma Corp.
KKRX:0419105,680.00
KRW
-50.00
(-0.87%)
ISIN
KR7041910001
Return %
Stock
S&P 500
1Y
-12.07
14.39
3Y
-7.94
81.42
5Y
-43.76
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Wong-Yeong Jo
- Full Time Employees
- 167
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hwaseong South Korea
- IPO Date
- Feb 6, 2004
- Website
- polarisaipharma.com
- Similar Companies
- Business
- Polaris AI Pharma Corp. is a South Korea-based pharmaceutical company that specializes in the research, development, manufacture, and commercialization of active pharmaceutical ingredients (APIs), generic drug substances, and specialized chemical intermediates, alongside contract development and manufacturing organization (CDMO) services and artificial intelligence-integrated pharmaceutical solutions. Founded in 1996 and headquartered in Hwaseong-si, Gyeonggi-do, South Korea, the company operates cGMP-compliant manufacturing facilities and supplies pharmaceutical companies domestically and across international markets, including Japan, Europe, and North America. The company's core product portfolio encompasses approximately 60 raw pharmaceutical ingredients across diverse therapeutic categories, including asthma treatments; peptic and gastric ulcer therapies; alcohol dependence treatments; anti-Parkinson's disease agents; anti-inflammatory medications; skeletal muscle relaxants; anti-diabetics; antihistamines; anti-rheumatic agents; cerebral function enhancers; capillary stabilizers; and MRI contrast agent intermediates. In addition to bulk active ingredients, Polaris AI Pharma Corp. offers comprehensive CDMO and custom research and manufacturing services (CRMS), utilizing specialized synthetic capabilities such as chiral synthesis, organometallic complex synthesis, micro-particulation, and organic synthesis, alongside a bio-venture incubation initiative that provides developmental and investment support to life science startups. In recent corporate developments, the company was acquired by the Polaris Office Group and officially changed its name from EstechPharma Co., Ltd. to Polaris AI Pharma Corp. in March 2024 to execute a strategic pivot toward AI-driven pharmaceutical technologies. Under this realignment, the company has partnered with affiliate Polaris Office Corp. to introduce AI-enabled synthetic pathway optimization, automated quality prediction, and proprietary domain-specific software solutions, including the retrieval-augmented generation (RAG) platform ASK-Doc for pharmaceutical documentation and research, while modernizing its production infrastructure through smart eco-factory implementations to advance environmental sustainability and accelerate global export expansion.